SecBot SecBot
SECBOTREPLAY Home › Report › BBIO

BBIO · BridgeBio announced a secondary offering of 5,000,000 shares by KKR…

BridgeBio Pharma, Inc. · PRESS-RELEASE filed Aug 13, 2026 at 17:42 ET

At the news

BEARISHIMPACT 5/10

PRESS-RELEASE filed Aug 13, 2026 at 17:42 ET

BridgeBio announced a secondary offering of 5,000,000 shares by KKR Genetic Disorder L.P., with the company receiving no proceeds. This overhang from a large existing holder selling into a $16.4B market cap creates moderate dilution pressure, though the company's strong Q2 revenue growth and upcoming PDUFA catalysts partially offset the sentiment. The offering follows a $1B preferred equity financing and positive Q2 results, suggesting KKR is taking partial profits rather than signaling distress.

  • KKR Genetic Disorder L.P. is selling 5,000,000 shares of BridgeBio common stock in a secondary public offering
  • BridgeBio will not receive any proceeds from the offering
  • William Blair, Goldman Sachs & Co. LLC and KKR are joint book-running managers
  • The offering is being made under an automatic shelf registration statement (Form S-3ASR) filed July 24, 2026

Replay the market's reaction

Step through every 5 minutes around the news, then see how it compares with similar events.

Subscribe for Full Access